시장보고서

상품코드

1873985

항응고제 역전제 시장

Anticoagulant Reversal Drugs Market

발행일: 2025년 11월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 150 Pages | 배송안내 : 1-5일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 항응고제 역전제 시장 규모는 2024년 14억 3,000만 달러로 평가되었고, 2031년까지 24억 4,000만 달러로 성장할 것으로 전망되며, 2024년-2031년 연평균 복합 성장률(CAGR)은 10.08%를 나타낼 전망입니다. 항응고제 역전제 시장에서는 혁신적인 제품의 도입과 발매가 중요한 동향이 될 전망입니다.

항응고제 역전제 시장 분석

최근 폐색전증(PE), 심부정맥혈전증(DVT), 심방세동(AF), 인공심장판 관련혈전증, 급성관증후군 등 다양한 심혈관질환의 예방·치료에서 항응고제의 사용이 급증하고 있습니다. 그러나 이러한 약물의 광범위한 사용은 심각한 출혈과 경미한 출혈의 위험을 초래하여 입원 및 응급 진찰을 초래할 수 있습니다. 이 위험은 항응고제와 항혈소판제 또는 이중 항혈소판 요법을 병용하는 복합 요법을 받는 환자에서 더욱 높아집니다. 와파린과 아스피린은 단독 사용 시 가장 높은 출혈 위험을 초래합니다. 따라서 항응고제 역전제는 출혈 위험을 줄이는 데 필수적입니다. 심방세동(AFib)의 유병률 증가와 뇌졸중 발생률의 상승은 환자의 결과 개선을 목적으로 하는 새로운 치료의 개발을 촉진할 것으로 예측됩니다.

항응고제 역전제 시장 개요

미국 질병예방관리센터(CDC)에 따르면 미국에서는 연간 45만 4,000건 이상의 심방세동관련 입원이 발생하여 약 15만 8,000명의 사망으로 이어지고 있습니다. 심방세동의 발병 위험은 노화와 함께 증가하고, 고령층에서 더 많이 보이는 고혈압도 심방세동 증례의 약 5분의 1에 기여하고 있습니다. 고령화 사회의 진전에 따라 향후 10년간 항응고제 역전제 수요가 확대될 것으로 예측되고 있습니다.

전략적 인사이트

항응고제 역전제 시장 성장 촉진요인과 기회

신경퇴행성 질환 및 언어 장애의 발생률 증가

항응고제 역전제는 출혈성 뇌졸중 관리에서 지속적인 출혈을 억제하고 조직 회복을 촉진하는 중요한 역할을합니다. 특히 저·중소득국에 있어서, 뇌졸중의 유병률은 상승 경향에 있습니다. 뇌졸중 계발재단의 보고에 의하면, 미국에서는 연간 약 79만 5,000명이 뇌졸중을 발병해, 14만명 이상이 사망하고 있습니다. 이 중 뇌졸중 관련 사망자의 약 40%가 남성, 60%가 여성입니다. 2021년 5월에 '완화의료 연보(Annals of Palliative Medicine, APM)'에 게재된 연구에서는 와파린 복용 중에 급성 허혈성 뇌졸중(AIS)을 발병한 환자에게 4인자 프로트롬빈 복합체 농축 제제, 신선 동결 혈장, 비타민 K1의 병용 투여를 실시했습니다. 따라서 뇌졸중 발생률 증가는 항응고제 역전제 시장에 중요한 촉진요인이 되고 있습니다.

신규 항응고제 역전제에서의 연구활동 확대에 따른 기회

심방세동과 같은 심혈관 질환 증가에 대처하는 새로운 치료법의 연구가 급속히 진행되고 있으며, 이는 항응고제 역전제 시장의 성장을 가속하고 있습니다. 다양한 심혈관 질환에 대한 혁신적인 치료법에 대한 수요는 지속적으로 존재합니다. 예를 들어, 2020년 7월 Journal of Thrombosis and Haemostasis에 발표된 ‘리바록사반 및 아픽사반 관련 두개내 출혈의 역전을 위한 안덱사넷 알파와 4인자 프로트롬빈 복합 농축액(4F-PCC) 평가’라는 연구에서는 안덱사넷 알파가 두개내 출혈(ICH) 치료에 얼마나 효과적인지 평가했습니다. 이러한 연구 이니셔티브 증가는 약물 발견 노력을 강화하고 업계 전체에서 시장 확대를 위한 수익성이 높은 기회를 창출하고 있습니다.

항응고제 역전제 시장의 세분화 분석

항응고제 역전제 시장 분석은 제품과 유통 채널로 구분됩니다.

제품별로는 프로트롬빈 복합체 농축 제제, 비타민 K, 프로타민, 트라넥삼산, 이달시주맙, 안덱사로 분류됩니다. 2023년에는 프로트롬빈 복합체 농축 제형 부문이 가장 큰 시장 점유율을 차지했습니다.
유통 채널별로는 원내 약국, 소매 약국, 기타로 구분되어, 2023년에는 병원 약국이 최대 시장 점유율을 차지했습니다.

항응고제 역전제 시장의 지역 분석

항응고제 역전제 시장 보고서의 지리적 범위는 북미, 아시아태평양, 유럽, 중동, 아프리카 및 중남미의 5개 지역으로 구분됩니다.

북미는 항응고제 역전제 시장을 선도하고 있으며 미국이 가장 큰 시장입니다. 이 지역의 성장은 주로 심방세동과 같은 심혈관질환의 유병률 증가, 시장기업의 기술진보, 미국의 주요기업의 존재에 의해 견인되고 있으며, 이들이 시장 성장을 더욱 가속시킬 전망입니다. 또한 미국에서 시장 기업의 전략적 노력이 시장 성장을 가속할 것으로 예측됩니다. 예를 들어, 2023년 6월, 아스트라제네카는 자사 제품 안덱사(안덱사넷 알파)에 대해 미국 및 EU에서 현행 조건부 승인에서 진보한 완전한 규제 신청 서류를 제출했습니다. 안덱사는 직접 경구 FXa 억제제의 항응고 작용을 신속하게 역전하도록 설계되었으며, 그 사용은 다양한 분야에 걸친 15개 이상의 국내 및 국제 지침에 의해 지원됩니다. 아스트라제네카는 현재 미국에서 완전한 적응 확대 승인을 추구하고 있습니다.

항응고제 역전제 시장 보고서 범위

항응고제 역전제 시장의 최근 동향

항응고제 역전제 시장은 주요 기업 간행물, 협회 데이터, 데이터베이스를 포함한 1차 조사와 2차 조사에서 수집한 정성적·정량적 데이터를 통해 평가되고 있습니다. 시장의 최근 동향의 일부를 아래에 소개합니다.

아스트라제네카 파마 인디아는 인자 Xa(FXa) 억제제와 관련된 생명을 위협하거나 난치성 출혈에 효과적인 치료제인 안덱사넷 알파의 수입 및 판매에 대해 인도 중앙 의약품 표준 관리기구(CDSCO)로부터 승인을 받았다고 발표했습니다.(출처: 아스트라제네카 파마, 보도 자료, 2024년)
옥타파마 USA는 비타민 K 의존성 응고 인자를 포함한 비활성화 4인자 프로트롬빈 복합체 농축 제형(4F-PCC) '발팩서'가 FDA 승인을 받았다고 발표했습니다. 발팩서는 비타민 K 길항제(VKA) 요법에 의한 후천성 응고 인자 결핍의 긴급 역전을 응급 수술 또는 침습적 치료가 필요한 성인 환자에서 적응시키고 와파린 요법으로 인한 응고 인자의 부족을 보충함으로써 혈액 응고 기능의 회복을 지원합니다.(출처 : 옥타파마 USA사, 보도자료, 2023년)

항응고제 역전제 시장 보고서 커버 범위 및 아티팩트

"항응고제 역전제 시장 규모와 예측(2021-2031년)"이라는 제목의 본 보고서는 다음 영역을 포괄하는 종합적인 시장 분석을 제공합니다.

대상 범위에 포함되는 모든 주요 시장 부문에 있어서, 세계, 지역, 국가 레벨에서 시장 규모와 예측
시장 역학(촉진요인, 억제요인, 주요 기회 포함)
주요 장래 동향
상세한 PEST/Porter's Five Forces 분석 및 SWOT 분석
주요 시장 동향, 주요 기업, 규제, 최근 동향을 강조한 세계 및 지역별 시장 분석
업계정세와 경쟁 분석(시장집중도, 히트맵 분석, 주요기업, 최근 동향 포함)
상세한 기업 프로파일

항응고제 역전제 시장 점유율 : 제품별(2024년 및 2031년,%)
프로트롬빈 복합체 농축 제제
- 프로트롬빈 복합체 농축 제제 : 시장 수익과 예측(-2031년)
비타민 K
- 비타민K : 시장수익과 예측（-2031년）
프로타민
- 프로타민 : 시장 수익과 예측(-2031년)
트라넥사믹산
- 트라넥사믹산 : 시장 수익과 예측(-2031년)
이다루시주맙
- 이다루시주맙 : 시장 수익과 예측（-2031년）
안덱사
- 안덱사 : 시장 수익과 예측（-2031년）

제8장 항응고제 역전제 시장 : 유통 채널별

항응고제 역전제 시장 점유율 : 유통 채널별(2024년 및 2031년,%)
원내 약국
- 원내 약국 : 시장 수익과 예측(-2031년)
소매 약국
- 소매 약국 : 시장 수익과 예측(-2031년)
기타
- 기타 : 시장 수익과 예측(-2031년)

제9장 항응고제 역전제 시장 : 지역 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제10장 COVID-19 팬데믹이 세계의 항응고제 역전제 시장에 미치는 영향

북미
유럽
아시아태평양
중동 및 아프리카
중남미

제11장 항응고제 역전제 시장 및 업계 정세

시장에서 기업의 성장 전략(%)
유기적 발전
- 기업에 의한 유기적 발전
무기적 발전
- 기업에 의한 무기적 발전

제12장 기업 프로파일

Boehringer Ingelheim International GmbH
Pfizer Inc.
Octapharma AG
AMAG PHARMACEUTICALS, INC.
Fresenius Kabi AG
Alexion Pharmaceuticals, Inc.(Portola Pharmaceuticals)
CSL Limited
China Biologic Products, Inc
Grifols, SA
Shanghai RAAS Blood Products Co., Ltd.

제13장 부록

SHW 25.12.11

The Anticoagulant Reversal Drugs Market is anticipated to grow to US$ 2.44 billion by 2031, up from US$ 1.43 billion in 2024, reflecting a compound annual growth rate (CAGR) of 10.08% from 2031 to 2031. The introduction and launch of innovative products are expected to be significant trends in the anticoagulant reversal drugs market.

Analysis of the Anticoagulant Reversal Drugs Market

Recently, the use of anticoagulants has surged for the prevention and treatment of various cardiovascular issues, including pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), thrombosis related to mechanical heart valves, and acute coronary syndromes. However, the extensive use of these medications poses risks of both major and minor bleeding, which can lead to hospital admissions and emergency visits. This risk is heightened when patients are on combination therapies that include both anticoagulants and antiplatelet or dual antiplatelet therapies. Warfarin and aspirin, when used alone, present the highest bleeding risks. Consequently, anticoagulant reversal drugs are essential for mitigating bleeding risks. The increasing prevalence of atrial fibrillation (AFib) and rising stroke incidents are expected to drive the development of new treatments aimed at improving patient outcomes.

Overview of the Anticoagulant Reversal Drugs Market

According to the Centers for Disease Control and Prevention (CDC), over 454,000 hospitalizations related to AFib occur annually in the US, leading to approximately 158,000 deaths. The likelihood of developing AFib increases with age, and high blood pressure, which is also more prevalent in older populations, contributes to about 1 in 5 AFib cases. The growing elderly population is projected to boost the demand for anticoagulant reversal drugs over the next decade.

Strategic Insights

Drivers and Opportunities in the Anticoagulant Reversal Drugs Market

Increasing Incidence of Neurodegenerative Diseases and Speech Disorders

Anticoagulant reversal drugs play a crucial role in managing hemorrhagic strokes by reducing ongoing bleeding and facilitating tissue recovery. The prevalence of strokes is rising, particularly in low- and middle-income countries. The Stroke Awareness Foundation reports that approximately 795,000 people in the US experience a stroke each year, resulting in over 140,000 deaths. Of these, around 40% of stroke-related fatalities occur in men, while 60% are in women. A study published in the Annals of Palliative Medicine (APM) in May 2021 demonstrated that administering a combination of 4-factor prothrombin complex concentrate, fresh frozen plasma, and vitamin K1 to a patient on warfarin who suffered an acute ischemic stroke (AIS) resulted in neurological improvement and successful reversal of coagulation. Thus, the increasing incidence of strokes is a significant driver for the anticoagulant reversal drugs market.

Opportunities from Growing Research Activities in Novel Anticoagulant Reversal Drugs

Rapid advancements in research for new therapeutics to address the rising prevalence of cardiovascular diseases, such as atrial fibrillation, are propelling the growth of the anticoagulant reversal drugs market. There is a continuous demand for innovative treatment options for various cardiovascular conditions. For example, a study titled 'Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages,' published in July 2020 in the Journal of Thrombosis and Haemostasis, assessed the effectiveness of andexanet alfa in treating intracranial hemorrhages (ICH). The rise in research initiatives is enhancing drug discovery efforts and creating lucrative opportunities for market expansion across the sector.

Segmentation Analysis of the Anticoagulant Reversal Drugs Market

The analysis of the anticoagulant reversal drugs market is segmented by product and distribution channel.

By product, the market is categorized into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, and AndeXXa. The prothrombin complex concentrates segment accounted for the largest market share in 2023.
Regarding distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and others, with hospital pharmacies holding the largest market share in 2023.

Geographical Analysis of the Anticoagulant Reversal Drugs Market

The geographical scope of the anticoagulant reversal drugs market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America leads the anticoagulant reversal drugs market, with the US being the largest market. The growth in this region is primarily driven by the increasing prevalence of cardiovascular diseases such as atrial fibrillation, advancements by market players, and the presence of major companies in the US, which will further accelerate market growth. Additionally, strategic initiatives by market players in the US are expected to enhance market growth. For instance, in June 2023, AstraZeneca submitted full regulatory filings for its Andexxa (andexanet alfa) in the US and EU, progressing from its current conditional approval. Andexxa is designed to rapidly reverse the anticoagulation effects of direct oral FXa inhibitors, and its use is supported by over 15 national and international guidelines across various disciplines. AstraZeneca is now pursuing full label approval in the US.

Scope of the Anticoagulant Reversal Drugs Market Report

Recent Developments in the Anticoagulant Reversal Drugs Market

The anticoagulant reversal drugs market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments in the market for speech and language disorders:

AstraZeneca Pharma India Ltd. announced that it received approval from the Central Drugs Standard Control Organisation (CDSCO) in India to import and market Andexanet Alfa, a treatment effective for life-threatening or refractory bleeding associated with Factor Xa (FXa) inhibitors. (Source: AstraZeneca Pharma, Press Release, 2024)
Octapharma USA announced the FDA approval of Balfaxar, a non-activated four-factor prothrombin complex concentrate (4F-PCC) containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, along with antithrombotic Proteins C and S. Balfaxar is indicated for urgent reversal of acquired coagulation factor deficiency due to vitamin K antagonist (VKA) therapy in adult patients requiring urgent surgery or invasive procedures, helping to restore blood coagulation by replenishing deficient clotting factors caused by warfarin therapy. (Source: Octapharma USA, Inc, Press Release, 2023)

Coverage and Deliverables of the Anticoagulant Reversal Drugs Market Report

The report titled "Anticoagulant Reversal Drugs Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

Market size and forecast at global, regional, and country levels for all key market segments included in the scope
Market dynamics, including drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter's Five Forces and SWOT analysis
Global and regional market analysis highlighting key market trends, major players, regulations, and recent developments
Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
In-depth company profiles

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Anticoagulant Reversal Drugs Market and By Product
- 1.3.2 Global Anticoagulant Reversal Drugs Market and By Distribution Channel
- 1.3.3 Global Anticoagulant Reversal Drugs Market and By Geography

2. Anticoagulant Reversal Drugs Market and Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Anticoagulant Reversal Drugs Market and Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America and PEST Analysis
- 4.2.2 Europe and PEST Analysis
- 4.2.3 Asia Pacific and PEST Analysis
- 4.2.4 Middle East and Africa
- 4.2.5 South and Central America
4.3 Expert Opinion

5. Anticoagulant Reversal Drugs Market and Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rise in Prevalence of Atrial Fibrillation (AFib)
- 5.1.2 Increase in Prevalence of Stroke
5.2 Market Restraints
- 5.2.1 High Cost of Anticoagulant Reversal Drugs
5.3 Market Opportunities
- 5.3.1 Increasing Research Activities on Anticoagulant Reversal Drugs
5.4 Future Trends
- 5.4.1 Development and Launch of Innovative Products
5.5 Impact Analysis

6. Anticoagulant Reversal Drugs Market and Global Analysis

6.1 Global Anticoagulant Reversal Drugs Market Revenue Forecast And Analysis
6.2 Global Anticoagulant Reversal Drugs Market, By Geography - Forecast And Analysis
6.3 Market Positioning

7. Anticoagulant Reversal Drugs Marketand By Product

7.1 Overview
7.2 Anticoagulant Reversal Drugs Market Share, by Product, 2024 and 2031 (%)
7.3 Prothrombin Complex Concentrates
- 7.3.1 Overview
- 7.3.2 Prothrombin Complex Concentrates: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
7.4 Vitamin K
- 7.4.1 Overview
- 7.4.2 Vitamin K: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
7.5 Protamine
- 7.5.1 Overview
- 7.5.2 Protamine: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
7.6 Tranexamic Acid
- 7.6.1 Overview
- 7.6.2 Tranexamic Acid: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
7.7 Idarucizumab
- 7.7.1 Overview
- 7.7.2 Idarucizumab: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
7.8 Andexxa
- 7.8.1 Overview
- 7.8.2 Andexxa: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)

8. Anticoagulant Reversal Drugs Marketand By Distribution Channel

8.1 Overview
8.2 Anticoagulant Reversal Drugs Market Share, by Distribution Channel, 2024 and 2031 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Anticoagulant Reversal Drugs Marketand Revenue and Forecast to 2031 (USD Million)

9. Anticoagulant Reversal Drugs Market and Geographic Analysis

9.1 North America: Anticoagulant Reversal Drugs Market
- 9.1.1 Overview
- 9.1.2 North America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.1.3 North America: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
- 9.1.4 North America: Anticoagulant Reversal Drugs Market, by Distribution Channel, 2024 and 2031 (USD Million)
- 9.1.5 North America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.1.6 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.1.6.1 US: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.1.6.2 US: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
  - 9.1.6.3 US: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
- 9.1.7 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.1.7.1 Canada: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.1.7.2 Canada: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
  - 9.1.7.3 Canada: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
- 9.1.8 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.1.8.1 Mexico: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.1.8.2 Mexico: Anticoagulant Reversal Drugs Market, by Product, 2024 and 2031 (USD Million)
  - 9.1.8.3 Mexico: Anticoagulant Reversal Drugs Market, by Distribution Channel 2024 and 2031 (USD Million)
9.2 Europe: Anticoagulant Reversal Drugs Market
- 9.2.1 Overview
- 9.2.2 Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.2.3 Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.2.4 Europe: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.5 Europe: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.2.6 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.6.1 Germany: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.6.2 Germany: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.2.6.3 Germany: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.7 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.7.1 France: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.7.2 France: Anticoagulant Reversal Drugs Market, by Productand Revenue and Forecast to 2031 (USD Million)
  - 9.2.7.3 France: Anticoagulant Reversal Drugs Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.8 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.8.1 UK: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.8.2 UK: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.2.8.3 UK: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.9 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.9.1 Italy: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.9.2 Italy: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.2.9.3 Italy: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.10 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.10.1 Spain: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.10.2 Spain: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.2.10.3 Spain: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.2.11 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.11.1 Rest of Europe: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.2.11.2 Rest of Europe: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.2.11.3 Rest of Europe: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
9.3 Asia Pacific: Anticoagulant Reversal Drugs Market
- 9.3.1 Overview
- 9.3.2 Asia Pacific: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (USD Million)
- 9.3.3 Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.3.4 Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.5 Asia Pacific: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.3.6 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.6.1 China: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.6.2 China: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.3.6.3 China: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.7 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.7.1 Japan: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.7.2 Japan: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.3.7.3 Japan: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.8 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.8.1 India: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.8.2 India: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.3.8.3 India: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.9 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.9.1 South Korea: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.9.2 South Korea: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.3.9.3 South Korea: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.10 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.10.1 Australia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.10.2 Australia: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.3.10.3 Australia: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.3.11 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.11.1 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.3.11.2 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.3.11.3 Rest of Asia Pacific: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
9.4 Middle East and Africa: Anticoagulant Reversal Drugs Market
- 9.4.1 Overview
- 9.4.2 Middle East and Africa: Anticoagulant Reversal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
- 9.4.3 Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.4.4 Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.4.5 Middle East and Africa: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.4.6 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.6.1 Saudi Arabia: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.6.2 Saudi Arabia Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.4.6.3 Saudi Arabia Anticoagulant Reversal Drugs Market, Type and Revenue and Forecast to 2031 (USD Million)
- 9.4.7 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.7.1 UAE: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.7.2 UAE Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.4.7.3 UAE Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.4.8 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.8.1 South Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.8.2 South Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.4.8.3 South Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.4.9 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.9.1 Rest of Middle East and Africa: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.4.9.2 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.4.9.3 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
9.5 South and Central America: Anticoagulant Reversal Drugs Market
- 9.5.1 Overview
- 9.5.2 South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
- 9.5.3 South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
- 9.5.4 South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.5.5 South and Central America: Anticoagulant Reversal Drugs Market, by Country, 2024 and 2031 (%)
- 9.5.6 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.5.6.1 Brazil: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.5.6.2 Brazil: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.5.6.3 Brazil: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.5.7 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.5.7.1 Argentina: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.5.7.2 Argentina: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.5.7.3 Argentina: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
- 9.5.8 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.5.8.1 Rest of South and Central America: Anticoagulant Reversal Drugs Market and Revenue and Forecast to 2031 (USD Million)
  - 9.5.8.2 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Product and Revenue and Forecast to 2031 (USD Million)
  - 9.5.8.3 Rest of South and Central America: Anticoagulant Reversal Drugs Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)

10. Impact of COVID-19 Pandemic on Global Anticoagulant Reversal Drugs Market

10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Anticoagulant Reversal Drugs Marketand Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
- 11.3.2 Organic Developments Done By Companies
11.4 Inorganic Developments
- 11.4.1 Overview
- 11.4.2 Inorganic Developments Done By Companies

12. Company Profiles

12.1 Boehringer Ingelheim International GmbH
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Pfizer Inc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Octapharma AG
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 AMAG PHARMACEUTICALS, INC.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Fresenius Kabi AG
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 CSL Limited
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 China Biologic Products, Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Grifols, S.A.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Shanghai RAAS Blood Products Co., Ltd.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 Glossary of Terms